Sonoma Pharmaceuticals updates investor presentation; no material new disclosures

Sonoma Pharmaceuticals, Inc.

Presentation highlights stabilized hypochlorous acid products for dermatology, wound care, eye care, and other applications.
Company reports distribution in 55 countries via direct sales and partners.
No financial results, guidance, or material operational changes were announced.
Contains forward-looking statements with usual risk factors.
Filing is a routine Regulation FD disclosure of an updated corporate overview.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.